Lancet Regional Health-Europe最新文献

{"title":"Trends and variation in the incidence of hip fracture in England before, during, and after the COVID-19 pandemic (2014–2024): a population-based observational study","authors":"James Webster ,&nbsp;Emre Oguzman ,&nbsp;Eva J.A. Morris ,&nbsp;Sasha Shepperd ,&nbsp;Xavier L. Griffin ,&nbsp;Antony Johansen ,&nbsp;Raphael Goldacre","doi":"10.1016/j.lanepe.2025.101427","DOIUrl":"10.1016/j.lanepe.2025.101427","url":null,"abstract":"<div><h3>Background</h3><div>Hip fractures are a common serious injury in older adults. The COVID-19 pandemic had a substantial impact on hip fracture prevention services, but contemporary data on incidence are scarce. We investigated recent trends and variation in the incidence of hip fracture in England.</div></div><div><h3>Methods</h3><div>A population-based study was conducted of hip fracture hospital presentations in adults aged ≥50 years using English national secondary care data (January 2014–October 2024). Trends in incidence were compared across pre-pandemic (January 2014–February 2020), pandemic (March-2020–July-2021), and post-pandemic periods (August 2021–October 2024). Variation by age, sex, and area-level deprivation were explored.</div></div><div><h3>Findings</h3><div>From 2014 to 2024, there were 704,762 hip fractures in 669,101 patients. Age-standardised incidence rates steadily declined from 2014 to 2019 from a mean monthly rate of 28.0–26.4 per 100,000 population. Incidence rates were below expected levels during the pandemic (IRR 0.96, 95% CI 0.94–0.97) but above expected levels in the post-pandemic period (IRR 1.03, 95% CI 1.01–1.04), resulting in 5595 more hip fractures than expected from August 2021 to October 2024. Hip fractures were more common in women, but temporal trends were consistent by sex. Incidence rates were higher in the most compared with the least deprived quintile; these inequalities remained largely unchanged by 2024 (IRR, 95% CI 1.67 [1.45–1.93] in men; 1.30 [1.19–1.42] in women).</div></div><div><h3>Interpretation</h3><div>This study highlights an excess of hip fracture presentations to hospital since the COVID-19 pandemic, and continued disparities in incidence by deprivation, despite an overall decreasing long-term trend. More equitable prevention strategies are needed, such as through more widespread screening for fracture risk and better coverage of fracture liaison services.</div></div><div><h3>Funding</h3><div>Authors are supported by the <span>NIHR Oxford BRC</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"57 ","pages":"Article 101427"},"PeriodicalIF":13.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144828205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain","authors":"Mariano Provencio ,&nbsp;Manuel Cobo ,&nbsp;Delvys Rodriguez-Abreu ,&nbsp;Enric Carcereny ,&nbsp;Rafael López Castro ,&nbsp;Manuel Fernández Bruno ,&nbsp;Reyes Bernabé ,&nbsp;Joaquim Bosch-Barrera ,&nbsp;Bartomeu Massutí ,&nbsp;Alfredo Sánchez ,&nbsp;Ana Laura Ortega ,&nbsp;Maria Guirado ,&nbsp;Edel del Barco ,&nbsp;Carlos Camps ,&nbsp;Martín Lázaro-Quintela ,&nbsp;Manuel Dómine ,&nbsp;María Ángeles Sala ,&nbsp;Karla Medina ,&nbsp;José Luís González-Larriba ,&nbsp;Francisco Aparisi ,&nbsp;Cristina Martí Blanco","doi":"10.1016/j.lanepe.2025.101402","DOIUrl":"10.1016/j.lanepe.2025.101402","url":null,"abstract":"<div><h3>Background</h3><div>Among patients with lung cancer, treatment with novel oncological agents may influence the risk of developing Second Primary Cancers (SPCs). We aimed to evaluate the incidence of SPCs in patients with lung cancer according to the type of oncological treatment received.</div></div><div><h3>Methods</h3><div>We conducted an observational, prospective, nationwide study based on the Spanish Thoracic Tumour Registry (TTR), between August 2016 and March 2023. Eligible patients aged over 18 years, diagnosed with lung cancer, and who achieved tumour remission were included.</div></div><div><h3>Findings</h3><div>A total of 20,574 patients were included. After a median follow-up of 41.2 months (95% CI 40.2–42.2), 480 patients developed a SPC (2.3%). The overall incidence was higher among those treated with chemotherapy (2.9%) compared with those receiving immunotherapy (2.1%) or targeted therapy (1.5%) (p &lt; 0.001). The cumulative incidence of SPCs at 12 months for patients that received chemotherapy was 1.22% (95% CI 0.99–1.45), 0.85% (95% CI 0.62–1.08) for immunotherapy and 0.67% (95% CI 0.34–0.99) for targeted therapy (p &lt; 0.001). In the adjusted multivariate model, both immunotherapy and targeted therapy were associated with a reduced risk of SPCs: HR = 0.470 (95% CI 0.338–0.654) and HR = 0.701 (95% CI 0.574–0.855), respectively. Additional associated factors with SPCs included metastatic disease, HR = 0.456 (95% CI 0.377–0.552); history of tobacco use, HR = 1.599 (95% CI 1.127–2.269); and current smoking, HR = 1.319 (95% CI 0.923–1.884) p &lt; 0.001.</div></div><div><h3>Interpretation</h3><div>Patients treated with immunotherapy and targeted therapy exhibited a significantly lower incidence of SPCs. Tobacco use was a key associated factor. Strengthening oncological follow-up and promoting interventions to address modifiable risk factors are essential for optimising long-term outcomes in lung cancer survivors.</div></div><div><h3>Funding</h3><div>This study was supported by the <span>Spanish Lung Cancer Group (Fundación GECP)</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"56 ","pages":"Article 101402"},"PeriodicalIF":13.0,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing technology-facilitated violence against women: the unique position of health care providers","authors":"Hans Henri P. Kluge","doi":"10.1016/j.lanepe.2025.101417","DOIUrl":"10.1016/j.lanepe.2025.101417","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"56 ","pages":"Article 101417"},"PeriodicalIF":13.0,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial","authors":"Andrew Bryant ,&nbsp;Jan Lecouturier ,&nbsp;Giovany Orozco-Leal ,&nbsp;Victoria Brocklebank ,&nbsp;Sonya Carnell ,&nbsp;Thomas Chadwick ,&nbsp;Sarah Dunn ,&nbsp;Sally Johnson ,&nbsp;David Kavanagh ,&nbsp;Ciara Kennedy ,&nbsp;Michael Malina ,&nbsp;Emma Montgomery ,&nbsp;Colin Muirhead ,&nbsp;Yemi Oluboyede ,&nbsp;Luke Vale ,&nbsp;Chris Weetman ,&nbsp;Edwin Wong ,&nbsp;Neil S. Sheerin","doi":"10.1016/j.lanepe.2025.101392","DOIUrl":"10.1016/j.lanepe.2025.101392","url":null,"abstract":"<div><h3>Background</h3><div>Atypical Haemolytic Uraemic Syndrome is a rare disease, associated with high morbidity and mortality. Eculizumab, a monoclonal complement inhibitor, is an effective treatment but the optimal way to use this high-cost medication has not been determined. The SETS aHUS trial aimed to establish the safety of eculizumab withdrawal and the effectiveness of a monitoring protocol to detect disease relapse and reintroduction of treatment if relapse occurs.</div></div><div><h3>Methods</h3><div>The SETS aHUS multicentre, open label, prospective, single-arm trial enrolled participants from 15 UK hospitals. Patients over two years of age with aHUS who were receiving eculizumab therapy for at least six months were eligible to withdraw from treatment, replacing it with monitoring to assess disease activity and treatment re-introduction if relapse occurred. The primary outcome measure was harm to a participant as a consequence of eculizumab withdrawal. Participants met a primary outcome if there was a permanent reduction in estimated glomerular filtration rate, requirement for kidney replacement therapy or significant extra-renal manifestation of disease. The Bayes factor single arm binary model was used to monitor and analyse the trial data, applying pre-trial stopping rules. The trial is registered with the European Union Drug Regulating Authority (EudraCT 2017-003916-37) and is closed for recruitment.</div></div><div><h3>Findings</h3><div>One of 28 participants (3.6%) who withdrew from treatment met a primary outcome. Four of the 28 participants (14.3%) relapsed. Only participants with an identified cause of complement dysregulation relapsed. It was possible, by monitoring and rapid participant access, to reintroduce eculizumab treatment. Based on the pre-trial analysis plan, withdrawal from treatment may represent no greater risk to patients.</div></div><div><h3>Interpretation</h3><div>In this single arm study, for patients fulfilling trial entry criteria, which excluded some high-risk patients, withdrawal of eculizumab treatment with monitoring of disease activity was not associated with an increased risk of harm compared to continuation of eculizumab.</div></div><div><h3>Funding</h3><div><span>National Institute for Health and Care Research Health Technology Assessment programme</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"56 ","pages":"Article 101392"},"PeriodicalIF":13.0,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study","authors":"Martina Sester ,&nbsp;Neus Altet-Gomez ,&nbsp;Åse Bengaard Andersen ,&nbsp;Miguel Arias-Guillén ,&nbsp;Korkut Avsar ,&nbsp;Anne-Marte Bakken Kran ,&nbsp;Graham Bothamley ,&nbsp;Anne Christine Nordholm Breschel ,&nbsp;James Brown ,&nbsp;Dumitru Chesov ,&nbsp;Nelly Ciobanu ,&nbsp;Daniela Maria Cirillo ,&nbsp;Valeriu Crudu ,&nbsp;Malu de Souza Galvao ,&nbsp;Asli Görek Dilektasli ,&nbsp;José Dominguez ,&nbsp;Raquel Duarte ,&nbsp;Anne Ma Dyrhol-Riise ,&nbsp;Delia Goletti ,&nbsp;Harald Hoffmann ,&nbsp;Christoph Lange","doi":"10.1016/j.lanepe.2025.101416","DOIUrl":"10.1016/j.lanepe.2025.101416","url":null,"abstract":"<div><h3>Background</h3><div>In low tuberculosis (TB)-endemic countries, tuberculosis preventive therapy (TPT) is recommended for immunocompromised individuals with a positive immunodiagnostic test. This study aimed to assess the performance of the QuantiFERON-TB Gold Plus (QFT+) assay and predictive power for future tuberculosis in immunocompromised individuals.</div></div><div><h3>Methods</h3><div>In this prospective observational study, immunocompromised adults ≥18 years of age including people living with HIV (PLHIV), chronic renal failure, rheumatoid arthritis, solid-organ transplantation or stem-cell transplantation, and immunocompetent adults with and without TB-disease were recruited at 21 sites in 11 European countries and tested with the QFT+ assay. Individuals without TB-disease were followed up for the development of tuberculosis. TB incidence rates (IR) were calculated, stratified by QFT+ results and acceptance of TPT. This study is registered with <span><span>Clinicaltrials.gov</span><svg><path></path></svg></span>, <span><span>NCT02639936</span><svg><path></path></svg></span>.</div></div><div><h3>Findings</h3><div>A total of 2663 individuals (1115 female, 1548 male) were enrolled from 03/11/2015 to 29/03/2019. Persons without tuberculosis were followed up for at least two years. Among 1758 immunocompromised individuals without active tuberculosis, 13.6% had positive QFT+ results. Sensitivity and specificity for TB-disease were 70.0% (52.1–83.3%) and 91.4% (89.6–92.9%), respectively, in immunocompromised, and 81.4% (76.6–85.3%) and 96.0% (92.5–97.9%), respectively, in immunocompetent individuals. During 2457 cumulative years of follow-up among 932 individuals with chronic renal failure, rheumatoid arthritis, solid-organ transplantation or stem-cell transplantation, including 83 persons with a positive QFT+ test without TPT, no-one developed active tuberculosis. In contrast, among 642 PLHIV without TPT, one with an indeterminate QFT+ and 3/30 individuals with a positive QFT+ developed active tuberculosis; all had detectable HIV-replication and low CD4 T-cell counts (incidence 4.1 (95% CI (1.3–12.4) per 100 person-years). No individuals receiving TPT developed active tuberculosis during 269 years of follow-up.</div></div><div><h3>Interpretation</h3><div>In immunocompromised individuals in low TB-endemic countries, the 2-year-risk for active tuberculosis was highest among PLHIV with detectable HIV-replication and low CD4-counts. In this study, the QFT+ assay did not strongly predict progression to active tuberculosis, which emphasises the need to incorporate additional risk factors.</div></div><div><h3>Funding</h3><div>None.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"57 ","pages":"Article 101416"},"PeriodicalIF":13.0,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144780446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of rotigotine in patients with frontotemporal dementia: a phase 2, double-blind, randomized, placebo-controlled, multicenter trial","authors":"Giacomo Koch ,&nbsp;Martina Assogna ,&nbsp;Yasmine Gadola ,&nbsp;Antonella Alberici ,&nbsp;Francesco Di Lorenzo ,&nbsp;Sonia Bonnì ,&nbsp;Ilaria Borghi ,&nbsp;Emanuele Cerulli Irelli ,&nbsp;Lucia Mencarelli ,&nbsp;Michele Maiella ,&nbsp;Romina Esposito ,&nbsp;Elias Paolo Casula ,&nbsp;Valentina Pezzopane ,&nbsp;Alessia D'Acunto ,&nbsp;Francesca Candeo ,&nbsp;Matteo Ferraresi ,&nbsp;Gisella Guerrera ,&nbsp;Luca Battistini ,&nbsp;Enrico Premi ,&nbsp;Valeria Bracca ,&nbsp;Barbara Borroni","doi":"10.1016/j.lanepe.2025.101409","DOIUrl":"10.1016/j.lanepe.2025.101409","url":null,"abstract":"<div><h3>Background</h3><div>Frontotemporal dementia (FTD) is a common form of dementia with no approved pharmacological treatment. Clinical and experimental evidence suggest that dopaminergic transmission is impaired in FTD. Here we aimed at investigating the clinical impact of treatment with dopaminergic agonists in FTD.</div></div><div><h3>Methods</h3><div>This was a phase IIa 24-week randomized, double-blind, multicenter, placebo-controlled study, conducted in Italy from June 16th 2021 to April 30th 2023. Patients with a diagnosis of probable behavioral variant FTD (bvFTD) were randomly assigned in a 1:1:1 ratio to receive rotigotine transdermal patches at 4 mg/24 h, rotigotine transdermal patches at 6 mg/24 h, or placebo transdermal patches for 24 weeks. Randomization was centralized and performed using a double-blind covariate-adaptive scheme. The primary outcome was analyzed in the intention-to treat (ITT) population. The primary efficacy outcome measure was the change at 24-weeks from baseline in the Frontal Assessment Battery (FAB). The trial is completed and was registered on the <span><span>clinicaltrial.gov</span><svg><path></path></svg></span> website (<span><span>NCT04937452</span><svg><path></path></svg></span>).</div></div><div><h3>Findings</h3><div>A total of 128 patients were screened, of which 75 were randomized. 25 patients were randomized to receive Rotigotine 4 mg, 26 patients to Rotigotine 6 mg, and 24 patients to placebo. The mean age of patients was 66.5 ± 8 of which 31 (41%) were female. A total of 69 patients (92%) completed the study. The estimated mean change from baseline at 24 weeks in the FAB score in the ITT population was 0.18 (95% confidence interval [CI] −0.79 to 1.15) in the rotigotine 4 mg group, 0.89 (95% CI −0.09 to 1.88) in the rotigotine 6 mg group and 1.08 (95% CI 0.19–1.98) in the placebo group (rotigotine 4 mg vs placebo, −0.90; 95% CI −2.22 to 0.42; p = 0.18; rotigotine 6 mg vs placebo, −0.19; 95% CI −1.52 to 1.14; p = 0.77). No significant effect was found on secondary outcome measures. Adverse events were mild in all groups and more common in the rotigotine (4 mg: 4/25; 6 mg: 3/26) than in the placebo (1/24) group.</div></div><div><h3>Interpretation</h3><div>Rotigotine administration may not be a viable therapeutic option for enhancing frontal function, slowing disease progression, mitigating functional decline or ameliorating behavioral disturbances in bvFTD patients. The current findings provide data in a large sample of bvFTD that might be useful for the design of future clinical trials.</div></div><div><h3>Funding</h3><div>This trial was funded by a joint grant from the <span>Alzheimer Drug Discovery Foundation (ADDF)</span> and the <span>Association for Frontotemporal Degeneration (AFTD)</span> grant to GK and BB (GFTD-201902-2017958).</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"57 ","pages":"Article 101409"},"PeriodicalIF":13.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144770800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes registries—key enablers of high-quality care","authors":"Chantal Mathieu ,&nbsp;Stefano Del Prato","doi":"10.1016/j.lanepe.2025.101422","DOIUrl":"10.1016/j.lanepe.2025.101422","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"56 ","pages":"Article 101422"},"PeriodicalIF":13.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144779485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic disparities in incidence, treatment, and survival of intrahepatic cholangiocarcinoma: insights from a nationwide cohort study in Sweden","authors":"Juan Vaz ,&nbsp;Hannes Hagström ,&nbsp;Per Sandström ,&nbsp;Malin Sternby Eilard ,&nbsp;Magnus Rizell ,&nbsp;Ulf Strömberg","doi":"10.1016/j.lanepe.2025.101415","DOIUrl":"10.1016/j.lanepe.2025.101415","url":null,"abstract":"<div><h3>Background</h3><div>The incidence of intrahepatic cholangiocarcinoma (iCCA) is rising globally, yet the role of socioeconomic status (SES) in shaping disease burden and care within universal healthcare systems remains poorly understood. This study assessed SES-related disparities in the incidence, treatment, and survival of iCCA in Sweden.</div></div><div><h3>Methods</h3><div>National registry data were used to identify all adult cases of iCCA diagnosed from 2011 to 2021 (n = 1827). Data from the Swedish quality register for liver cancer were cross-linked with socioeconomic and healthcare registers. Household income– categorised as low (lowest national quartile), medium, or high (highest quartile)–was used as the SES indicator. Incidence rates (IRs), treatment patterns, and survival were analysed across income strata.</div></div><div><h3>Findings</h3><div>The age-standardized IR increased from 1.35 in 2011 to 1.94 per 100,000 person-years in 2021, with the steepest rise observed among men and individuals with low income. Compared to those with high-income, individuals with low income had higher IR ratios of all-stage (1.32, 95% confidence interval [CI]: 1.15–1.52) and late-stage iCCA (1.46, 95% CI: 1.17–1.81). Preventable liver diseases were more prevalent in the low-income patients, while primary sclerosing cholangitis and inflammatory bowel disease were more common among high-income patients. Low income was associated with lower odds of receiving systemic therapy (adjusted odds ratio 0.54, 95% CI: 0.38–0.77) and higher mortality risk among those treated (adjusted hazard ratio 1.34, 95% CI: 1.09–1.65).</div></div><div><h3>Interpretation</h3><div>Despite universal healthcare access, substantial socioeconomic disparities persist in the incidence, treatment, and outcomes of iCCA in Sweden.</div></div><div><h3>Funding</h3><div>The <span>Swedish Cancer Society</span> and The <span>Royal Swedish Academy of Sciences</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"57 ","pages":"Article 101415"},"PeriodicalIF":13.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144770799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Portrayal and social response to the new era of medications for obesity","authors":"Stuart W. Flint ,&nbsp;Clara Almazán","doi":"10.1016/j.lanepe.2025.101426","DOIUrl":"10.1016/j.lanepe.2025.101426","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"57 ","pages":"Article 101426"},"PeriodicalIF":13.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144766708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From waste to sustainability: a European call to action on responsible disposal of unused and expired household medications","authors":"Przemysław Kardas ,&nbsp;Justyna Rogowska ,&nbsp;Maria Eugenia Beltrán Jaunsarás ,&nbsp;Bart van den Bemt ,&nbsp;Tamás Ágh","doi":"10.1016/j.lanepe.2025.101425","DOIUrl":"10.1016/j.lanepe.2025.101425","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"56 ","pages":"Article 101425"},"PeriodicalIF":13.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144771503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}